Cancer patients who responded to drug can continue treatment in new study
NCT ID NCT07415031
First seen Feb 27, 2026 · Last updated May 15, 2026 · Updated 6 times
Summary
This study is for people with advanced solid tumors (like lung or colorectal cancer) who have already been helped by the drug adagrasib in a previous trial. It allows them to keep receiving the treatment and monitors any side effects. The goal is to provide continued care and gather more safety information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Local Institution - 0001
St. Petersburg, Florida, 33701, United States
Contact
-
Local Institution - 0002
Grapevine, Texas, 76051, United States
Contact
-
Local Institution - 0003
Newark, Delaware, 19713, United States
-
Local Institution - 0004
Eugene, Oregon, 97401, United States
Contact
-
Local Institution - 0005
Phoenix, Arizona, 85054, United States
-
Local Institution - 0006
Badalona, Barcelona, 08916, Spain
Contact
-
Local Institution - 0007
A Coruña, A Coruña [La Coruña], 15006, Spain
Contact
-
Local Institution - 0008
Seville, 41009, Spain
Contact
-
Local Institution - 0009
Madrid, 28027, Spain
Contact
-
Local Institution - 0010
Barcelona, Barcelona [Barcelona], 08028, Spain
Contact
-
Local Institution - 0011
Palma de Mallorca, 07010, Spain
Contact
-
Local Institution - 0012
München, 81737, Germany
Contact
-
Local Institution - 0013
Bellingham, Washington, 98225, United States
Contact
-
Local Institution - 0014
Lisbon, Lisbon District, 1099-023, Portugal
Contact
-
Local Institution - 0015
Madrid, 28040, Spain
Contact
-
Local Institution - 0016
Bellflower, California, 90706, United States
Contact
-
Local Institution - 0017
Rochester, Minnesota, 55905, United States
Contact
-
Local Institution - 0018
Málaga, 29010, Spain
Contact
-
Local Institution - 0023
Germantown, Tennessee, 38138, United States
Contact
-
Local Institution - 0024
Madid, 28034, Spain
Contact
-
Local Institution - 0025
Barcelona, 08036, Spain
Contact
-
Local Institution - 0027
Córdoba, 14004, Spain
Contact
-
Local Institution - 0028
East Syracuse, New York, 13057, United States
Contact
-
Local Institution - 0029
Barcelona, 08035, Spain
Contact
-
Local Institution - 0030
Santander, Cantabria, 39008, Spain
Contact
-
Local Institution - 0036
Omaha, Nebraska, 68114, United States
Contact
-
Local Institution - 0060
Craiova, Dolj, 200746, Romania
Contact
-
Local Institution - 0064
Chicago, Illinois, 60637, United States
Contact
-
Local Institution - 0072
Vancouver, British Columbia, V5Z 4E6, Canada
Contact
-
Local Institution - 0073
Saint Paul, Minnesota, 55101, United States
Contact
Conditions
Explore the condition pages connected to this study.